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Abstract: Patients with myelodysplastic syndromes (MDS) are challenging to treat, given 
the advanced median age and comorbidities of the population. For most patients, the standard 
therapy is supportive care, including broad-spectrum antibiotics, red blood cell/platelet transfu-
sions, and growth factors. Decitabine, a hypomethylating agent that allows for the re-expression 
of tumor suppressor genes, represents an exciting new treatment option for MDS patients. In 
phase 2 and 3 studies, decitabine has been associated with durable responses in MDS patients 
and delayed time to acute myeloid leukemia (AML) transformation or death compared with 
supportive care. Decitabine has been shown to be well tolerated with a toxicity proﬁ  le expected 
for this class of agent. Recent studies also suggest that lower dose schedules of decitabine 
may result in additional improvements in response. As more is learned about the mechanism 
of hypomethylating agents, new roles are emerging for decitabine in combination therapy for 
MDS and in other hematologic malignancies such as AML.
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Myelodysplastic syndromes
Myelodysplastic syndromes (MDS) are a group of bone marrow disorders characterized 
by ineffective hematopoiesis resulting in anemia, neutropenia, and thrombocytopenia 
(American Cancer Society 2005; Myelodysplastic Syndromes Foundation 2006; 
American Cancer Society 2006). MDS can be classiﬁ  ed as de novo, arising from 
no apparent cause, or as secondary, resulting from exposure to a mutagen such as 
chemotherapy or benzene (American Cancer Society 2005; Aplastic Anemia & MDS 
International Foundation 2005). Chromosomal abnormalities are common in both types 
of MDS (Kurzrock 2002; List et al 2004; American Cancer Society 2005; American 
Cancer Society 2006). In patients with de novo MDS, chromosomal abnormalities 
have been reported in approximately 40%–70% of cases, whereas in patients with 
secondary MDS, chromosomal abnormalities are observed in almost 95% of cases 
(List et al 2004). MDS occurs primarily in the elderly and is rare in young adults 
(Williamson et al 1994; Aul et al 1998; American Cancer Society 2005; American 
Cancer Society 2006).
Although the exact number of MDS cases is unknown owing to the lack of a central 
United States registry, it is estimated that, in the general population, MDS occurs in 
5 per 100,000 people (National Comprehensive Cancer Network 2006). Estimates 
range between 10,000 and 20,000 new cases of MDS per year in the United States 
(American Cancer Society 2005; Aplastic Anemia & MDS International Foundation 
2005). The number of MDS cases is believed to be increasing as a result of the aging 
population and the increased survival rate of patients who have received chemotherapy 
(American Cancer Society 2005).Therapeutics and Clinical Risk Management 2007:3(5) 808
Saba
The greatest risk factor for MDS appears to be advanc-
ing age, with 80%–90% of all patients over 60 years old 
(American Cancer Society 2005). Other risk factors for 
MDS are previous chemotherapy, exposure to environ-
mental toxins, tobacco and cigarette smoke, congenital 
disorders, familial disorders, and being of male gender 
(American Cancer Society 2005). Clinical symptoms may 
include fatigue, weakness, and serious infections; however, 
approximately half of MDS patients are asymptomatic at 
the time of initial diagnosis and are diagnosed only after 
routine laboratory tests show abnormalities (Hofmann and 
Koefﬂ  er 2005; American Cancer Society 2005; Aplastic 
Anemia & MDS International Foundation 2005). Although 
MDS can eventually result in neutropenia and/or throm-
bocytopenia, anemia is the most common characteristic 
at the time of initial diagnosis. In the early course of the 
disease, a hemoglobin value of less than 10 g/dL has been 
observed in approximately 80% of patients (Hofmann and 
Koefﬂ  er 2005).
Prognosis can depend on many variables, including mor-
phology, number of cytopenias, blast count, and cytogenetics. 
Left untreated, the median survival ranges from 0.4 years 
for high-risk MDS patients to 5.7 years for low-risk MDS 
patients (Greenberg et al 1997). In the majority of MDS 
patients, death typically results from complications of bone 
marrow failure, such as chronic anemia, infections, or severe 
bleeding (Kurzrock 2002; Myelodysplastic Syndromes 
Foundation and Bennett 2006). Approximately one-third 
of adult MDS patients progress to acute myeloid leukemia 
(AML), with a median survival of 6–12 months (Ganser and 
Hoelzer 1992; Greenberg et al 1997).
Classiﬁ  cation systems
At the present time there are two MDS classification sys-
tems that have been used to determine expected median 
survival and median time to AML transformation. The 
French-American-British (FAB) Co-operative Group 
Classification recognizes five subgroups of MDS based 
on cell morphology and the percentage of blasts (Bennett 
et al 1982). In order to improve the prognostic value, the 
World Health Organization (WHO) subsequently made 
modifications to FAB that included the reduction of the 
blast threshold for the diagnosis of AML and refinements 
of the categories of refractory anemia (RA) and refrac-
tory anemia with ringed sideroblasts (RARS) (Vardiman 
et al 2002).
There has also been the development of a widely used 
prognostication tool, the International Prognostic Scoring 
System (IPSS), which takes into account cytogenetics and 
number of cytopenias as well as morphology (Greenberg et al 
1997; Kurzrock 2002). The IPSS scoring system subdivides 
MDS into four distinct subgroups for predicting survival 
and risk of transformation to AML (Table 1) (Greenberg 
et al 1997).
Table 1 International prognostic scoring system (IPSS) score and prognosis
 Scorea
Prognostic
variable 0  0.5  1  1.5  2.0
Marrow blasts (%)  <5  5–10  —  11–20   21–30 
Karyotypeb Good  Intermediate  Poor  NA  NA
Cytopeniasc 0/1  2/3  NA  NA  NA
Combined   IPSS subgroup  Median time to AML   Medial survival (yrs)
prognosis score    transformation, 25% of  
   patients  (yrs) 
0 Low  9.4  5.7
0.5–1.0 Intermediate-1  3.3  3.5
1.5–2.0 Intermediate-2  1.1  1.2
>2.5 High  0.2  0.4
aBased on the combined score, four risk groups have been identiﬁ  ed: low (combined score: 0), intermediate-1 (combined score: 0.5–1), intermediate-2 (combined score: 
1.5–2), and high (combined score: 2).
bGood: diploid, -Y (loss of the Y chromosome); del(5q), del(20q), deletion of 5q and 20q chromosomes; poor: complex, chromosome 7 abnormalities; intermediate: others.
cHemoglobin 10g/dL, neutrophils 1.5 × 109/L, platelets 100 × 109/L.
NA, not applicable;  AML, acute myeloid leukemia.
Source: Adapted, with permission, from “International scoring system for evaluating prognosis in myelodysplastic syndromes” (Greenberg et al 1997) p2085. Copyright 
1997 by the American Society of Hematology.Therapeutics and Clinical Risk Management 2007:3(5) 809
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Clinical practice guidelines
Evidence-based treatment guidelines for MDS have recently 
been published by the Italian Society of Hematology, the 
United Kingdom, and the United States (National Compre-
hensive Cancer Network [NCCN]) (Alessandrino et al 2002; 
Bowen et al 2003; National Comprehensive Cancer Network. 
2006). According to these guidelines, the treatment strategy 
for MDS should be determined by IPSS risk category, as well 
as age and performance status. The recently updated NCCN 
guidelines recommend hypomethylating agents, such as 
decitabine or azacitidine, for the treatment of higher risk MDS 
patients and for lower risk MDS patients who are nonrespon-
sive to growth factor therapy or who are HLA-DR15 negative 
(National Comprehensive Cancer Network. 2006).
Treatment options
The MDS patient population presents many challenges when 
considering an appropriate treatment strategy, including 
advanced age, comorbidities, and an inability to tolerate 
certain types of intensive therapy. Therapy should be selected 
based on the patient’s performance status, disease classiﬁ  ca-
tion, IPSS score, and treatment tolerance. In patients with a 
low-risk or intermediate-1 IPSS score, the goals of therapy 
are to improve blood counts and ensure age-related quality 
of life (National Comprehensive Cancer Network. 2006), 
whereas for intermediate-2 and high-risk patients, the goals of 
therapy are to prolong survival and delay leukemic progres-
sion (National Comprehensive Cancer Network. 2006). The 
only potentially curative treatment for MDS is hematopoietic 
stem cell transplantation (HSCT), however, this option is 
available for only a small number of patients (ie, younger 
age, histocompatible donor, no signiﬁ  cant comorbidities) 
(Alessandrino et al 2002; Bowen et al 2003; National Com-
prehensive Cancer Network. 2006). Some high-risk MDS 
patients who are not candidates for HSCT may be eligible 
for intensive antileukemic chemotherapy (Alessandrino et al 
2002; Bowen et al 2003; National Comprehensive Cancer 
Network. 2006). Nevertheless, the vast majority of MDS 
patients are managed with supportive care, including red 
blood cell (RBC)/platelet transfusions, growth factors such 
as recombinant erythropoietin and colony-stimulating fac-
tors, and antibiotics, including broad coverage in neutropenic 
patients as infection occurs.
A number of emerging therapeutic options are currently 
being evaluated for the treatment of MDS that will, it is hoped, 
add to the treatment options for patients who are ineligible 
to receive HSCT or intensive chemotherapy. Lenalidomide, 
an immunomodulatory drug derived from thalidomide, has 
been recently approved by the Food and Drug Administration 
(FDA) and is indicated for the treatment of MDS in patients 
with chromosome 5q deletion. Other agents such as imatinib 
and tipifarnib are currently being evaluated in clinical trials 
(Cortes et al 2003; Feldman 2005; Sekeres 2005; Jabbour 
and Giles 2005). Some of the therapies farthest along in 
development are the hypomethylating agents decitabine and 
azacitidine, both of which have been recently approved by 
the FDA for the treatment of MDS.
Hypermethylation in cancer
DNA methylation is a common epigenetic modiﬁ  cation that 
plays an important role in gene expression in mammalian 
cells (Leone et al 2002; Das and Singal 2004). As part of 
normal development, certain genes may be silenced through 
methylation of cytosine residues in their promotor regions 
(CpG islands). However, in some hematopoietic neoplasms 
including MDS, DNA hypermethylation can inactivate genes 
essential for the control of normal cell growth, differentia-
tion, or apoptosis. A group of enzymes called DNA methyl-
transferases (DNMTs) catalyze the methylation of cytosine 
residues in newly synthesized DNA, thus replicating the 
methylation signal. In recent years, there has been interest 
in pharmacologic therapies that target this mechanism by 
inhibiting DNMT, resulting in hypomethylation of the DNA 
and re-expression of tumor suppressor genes. Cytosine ana-
logues such as decitabine have been shown to inhibit DNMT 
and are being used against MDS, as well as AML and other 
cancers (Leone et al 2002; Das and Singal 2004).
Multiple genes appear to be hypermethylated in MDS, 
including p15INK4B, which encodes a cell-cycle inhibitor. 
Evidence suggests that p15INK4B methylation is corre-
lated with blastic bone marrow involvement and that it 
increases during disease progression to AML (Quesnel 
et al 1998; Quesnel and Fenaux 1999). Methylation of 
the p15INK4B gene may allow leukemic cells to escape the 
inhibitory signals in the bone marrow (Quesnel et al 1998; 
Quesnel and Fenaux 1999). Decitabine treatment has been 
shown to reverse hypermethylation of p15INK4B, allowing 
for re-establishment of normal p15INK4B protein expres-
sion (Daskalakis et al 2002). In addition, hypomethyl-
ation of p15INK4B has been associated with hematologic 
response, supporting pharmacologic demethylation as a 
possible mechanism for clinical response (Daskalakis 
et al 2002).
Decitabine is believed to have a dual mechanism 
of action depending on dose. At both lower and higher 
doses, decitabine incorporates into DNA; however, at Therapeutics and Clinical Risk Management 2007:3(5) 810
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higher doses, decitabine inhibits cell proliferation through 
nonreversible covalent linking with DNA methyltransfer-
ase and blocking of DNA synthesis (Leone et al 2002). At 
lower doses, decitabine induces hypomethylation, thereby 
promoting cell differentiation, re-expression of tumor 
suppressor genes, stimulation of immune mechanisms, 
and suppression of tumor growth (Leone et al 2002; 
Mund et al 2005).
Description and structure
of decitabine
Decitabine (5-aza-2'-deoxycytidine) is a cytosine analogue 
modiﬁ  ed in position 5 of the pyrimidine ring (Figure 1). 
Decitabine is slightly soluble in ethanol/water (50/50), 
methanol/water (50/50), and methanol; sparingly soluble in 
water; and soluble in dimethylsulfoxide (DMSO). Decitabine 
(Dacogen™ for Injection) is a white to almost-white sterile 
lyophilized powder supplied in a clear, colorless glass vial 
(Dacogen 2006).
Pharmacokinetics
Decitabine distributes extensively throughout human 
tissues. In a phase 1 pharmacokinetic study of decitabine 
in 21 patients with advanced solid tumors, the mean value 
of volume of distribution was found to be 4.59 L/kg ± 1.42 
(van Groeningen et al 1986). Although the exact route of 
elimination and metabolic fate of decitabine is unknown in 
humans, high total body clearance values and a total urinary 
excretion of less than 1% of the administered dose suggest 
that decitabine is eliminated rapidly and primarily through 
enzymatic metabolism (van Groeningen et al 1986).
In a more recent pharmacokinetic phase 1 study, 16 
patients with MDS/AML were administered decitabine at a 
dose of 15 mg/m2 as a 3-hour infusion every 8 hours for 3 
consecutive days of a 6-week cycle for two cycles (Cashen 
et al 2005). Preliminary results suggest that repeated adminis-
tration of decitabine does not result in systemic accumulation 
of the drug. For the ﬁ  ve patients who received decitabine 
for two cycles, maximum concentration (Cmax) values for 
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Cycle 1 (49.0 ± 22.2 ng/mL) and Cycle 2 (62.7 ± 45.2 ng/mL) 
were comparable, suggesting that decitabine pharmacokinet-
ics remain unchanged from cycle to cycle.
Clinical studies of decitabine
Phase 2 studies of decitabine in MDS patients yielded encour-
aging response rates, including overall responses (complete 
response [CR] + partial response [PR]) of 26%–45% and 
complete responses of 21%–28% (Wijermans et al 1997; 
Wijermans et al 2000; Saba et al 2005; Saba and Wijermans 
2005). These results led to a North American, multicenter 
phase 3 study of decitabine compared with supportive care 
in 170 MDS patients, which formed the basis for the FDA 
approval of decitabine (Saba et al 2004; Kantarjian et al 
2006). Patients were stratiﬁ  ed by IPSS risk group and type 
of MDS (de novo or secondary) and randomly assigned to 
receive either supportive care alone or decitabine at a dose 
of 15 mg/m2 as a 3-hour infusion every 8 hours for 3 days, 
repeated every 6 weeks, plus supportive care. Primary end-
points were overall response rate (ORR) and time to AML 
transformation or death. Responses were assessed using the 
International Working Group (IWG) criteria (Cheson et al 
2000), which deﬁ  ned a CR as normalization of peripheral 
counts and bone marrow for at least 8 weeks with serial bone 
marrow blasts less than 5% without dysplastic changes, hemo-
globin greater than 11 g/dL, a neutrophil count 1.5 × 109/L 
or greater, and a platelet count of 100 × 109/L or greater. A 
PR was deﬁ  ned similarly to CR except for the reduction of 
50% of blasts that remained above 5%, or a downgrade in 
the FAB criteria. Response criteria had to be met for at least 
8 weeks. The study design dictated that patients be removed 
from therapy after two cycles of a maintained CR.
The results of the phase 3 study indicate that decitabine 
is clinically effective in patients with MDS. Patient baseline 
characteristics were well balanced between the two study 
arms. Responses were deﬁ  ned according to strict IWG cri-
teria (Cheson 2000). The ORR of patients in the decitabine 
arm was 17% compared with 0% in the supportive care only 
arm (p  0.001) (Table 2). In decitabine-treated patients 
considered evaluable for response (ie, those patients with 
pathologically conﬁ  rmed MDS at baseline who received at 
least two cycles of treatment), the ORR was 21% (12/56) 
(McKeage and Croom 2006). Responses were observed 
across all IPSS risk groups and were found to be durable, 
with a median duration of response of 10.3 months (Table 2). 
Median time to ﬁ  rst response (PR or CR) was 3.3 months 
(Table 2). Hematologic improvement (HI) was observed in 
an additional 13% of patients in the decitabine group versus 
7% in the supportive care arm. The overall improvement 
rate for patients receiving decitabine was 30% versus 7% for 
patients receiving supportive care. Patients in the decitabine 
arm had a median time to AML or death that was 4.3 months 
greater than that of patients in the supportive care only arm 
(p = 0.16) (Figure 2A). When patient subgroups were ana-
lyzed, patients receiving decitabine experienced a longer 
time to AML or death than patients receiving supportive 
care only (treatment-naïve [12.3 vs 7.3 months; p = 0.08] 
[Figure 2B], IPSS risk of intermediate-2/high-risk patients 
[12.0 vs 6.8 months; p = 0.03] [Figure 2C], IPSS high-risk 
patients [9.3 vs 2.8 months; p = 0.01], or de novo MDS [12.6 
vs 9.4 months; p = 0.04]).
All responders in the phase 3 study, deﬁ  ned as patients 
achieving a CR or PR, became RBC and platelet transfusion 
independent in the absence of growth factors during the time 
of the response (Saba et al 2004; Saba and Wijermans 2005; 
Kantarjian et al 2006). The percentage of patients in the 
decitabine arm who became RBC transfusion independent 
increased with increased number of treatment cycles, while 
the percentage of patients on supportive care who required 
RBC transfusions did not change (Figure 3). All eight 
Table 2 Response to decitabine (ITT) using the FDA approved dose of 15 mg/m2 over 3 hours every 8 hours × 3 days every 6 weeks 
(Adapted, with permission, from Kantarjian et al (2006))
International working group response rate,  Decitabine  Supportive care
onset, and duration  (n = 89)  (n = 81)
Overall response rate (CR + PR)  15(17%)*  0(0%)
CR  8(9%) 0(0%)
PR  7(8%) 0(0%)
HI  12(13%) 6(7%)
*p-value < 0.001 from two-sided Fisher’s exact test
Onset and duration of response (months)
Median time to (CR + PR) response  3.3(2.0 – 9.7) 
Median duration of (CR + PR) response  10.3(4.1 – 13.9)  N/A
Abbreviation: ITT, intention to treat; CR, complete response; PR, partial response; HI, hematologic improvement.Therapeutics and Clinical Risk Management 2007:3(5) 812
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responders who had cytogenetic abnormalities at baseline 
and were evaluable for cytogenetic response achieved a 
cytogenetic response (seven major responses and one minor 
response). The median number of cycles delivered was three, 
with 43 of 89 patients receiving two or more cycles. Of the 
15 patients who responded after decitabine treatment, the 
median number of courses was six. In contrast, the median 
number of cycles in the phase 2 studies was four, which may 
in part explain the slightly higher response rates in the phase 
2 studies (Saba et al 2005). The authors of the phase 3 study 
speculate that greater beneﬁ  t may have been observed if 
the study design had allowed patients to continue receiving 
decitabine therapy for a longer period of time.
Safety data were evaluated for 83 patients treated with 
decitabine and 81 patients who received supportive care only. 
Overall, decitabine therapy was well tolerated with man-
ageable adverse effects. The most common adverse effects 
included myelosuppression (neutropenia, thrombocytopenia, 
and anemia), pyrexia, fatigue, nausea, cough, petechiae, 
diarrhea, and constipation (Table 3). Febrile neutropenia 
occurred in 28% of patients who received decitabine. The 
authors noted that neutropenia, thrombocytopenia, anemia, 
and leukopenia appeared to diminish in incidence over the 
ﬁ  rst four cycles of decitabine treatment; however, these tox-
icities remained frequent, most likely owing to the continuing 
presence of underlying disease and myelosuppression.
Decitabine has also been studied in MDS patients with 
disease recurrence who had previously responded to the 
drug. Rüter and colleagues reported recently on 22 patients 
who received decitabine retreatment at the time of disease 
relapse (Lubbert et al 2004; Ruter et al 2006). These patients 
had initially received a median of six courses of decitabine 
(range 2–6 courses), which resulted in a CR in 55% (12 
of 22 patients), a PR in 27% (6 of 22), and a hematologic 
improvement in 18% (4 of 22). Decitabine retreatment was 
initiated at a median of 11 months after the last course of 
initial treatment. In the retreatment stage, patients received a 
median of three courses, resulting in 45% (10 of 22 patients) 
of patients responding (7 HI, 2 PR, and 1 CR). The median 
duration of second response was 4 months. Because the 
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quality and duration of the second response were inferior to 
those of the ﬁ  rst response, the authors suggest that decitabine 
responders may derive more clinical beneﬁ  t from a longer 
period of initial treatment.
Optimal dosing of decitabine
As previously described, decitabine is believed to have a dual 
mechanism of action depending on dose, with higher doses 
associated with cytotoxicity and lower doses associated with 
demethylation. Because of this dose-dependent mechanism 
of action, lower-dose schedules of decitabine may be safer 
and more effective than higher dose schedules. Indeed, early 
studies of decitabine using high doses of the drug showed 
activity in various types of hematologic malignancies but 
with signiﬁ  cant prolonged myelosuppression (Santini et al 
2001). In a more recent study, decitabine appeared signiﬁ  -
cantly more active at lower doses compared with higher doses 
(Issa et al 2004).
In order to further optimize therapy with decitabine, 
Kantarjian and colleagues performed a randomized study of 
three low-dose schedules in patients with MDS and chronic 
myelomonocytic leukemia (CMML) (O’Brien et al 2005; 
Kantarjian et al 2005; Kantarjian et al 2007). The decitabine 
dose per course was reduced from the FDA approved dose of 
135 mg/m2 to 100 mg/m2. In addition, the doses of decitabine 
were delivered every 4 weeks (rather than every 6–8 weeks), 
as long as there was persistent disease and no signiﬁ  cant 
myelosuppression-associated complications, and therapy 
was continued for at least three courses before response 
was evaluated. The three dosing schedules were as follows: 
20 mg/m2 intravenously (IV) over 1 hour daily for 5 days 
(arm A), 10 mg/m2 IV over 1 hour daily for 10 days (arm 
B), and 10 mg/m2 subcutaneously (SQ) given twice daily 
for 5 days (arm C).
The results of the study by Kantarjian and colleagues 
indicate that lower dose schedules of decitabine have higher 
efﬁ  cacy in MDS patients (O’Brien et al 2005; Kantarjian 
et al 2005; Kantarjian et al 2007). At least one course of 
therapy was received by 95 patients. Response criteria for 
CR and PR were the same as for AML (PR also requiring a 
decrease in blasts by >50%) but required response durability 
for at least 4 weeks. In total, 32 patients had a CR (34%), 
1 patient had a PR (1%), 23 patients (24%) had marrow CR 
without (n = 10, 11%) or with other HI responses (n = 13, 
14%), and 13 patients had an HI (14%). When analyzed by 
schedule, the complete response rates were 39% for arm A, 
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24% for arm B, and 21% for arm C (Table 4). The median 
number of courses to reach CR for all treatment groups was 
three (range, 1–7). Myelosuppression was the primary toxic-
ity reported and it occurred more with arm B (Table 4). In 
summary, the schedule of 20 mg/m2 IV over 1 hour daily for 
5 days was found to be superior to the other two regimens 
and to offer an excellent therapeutic option in addition to the 
FDA approved dose (Table 5).
Approved indications for decitabine
Decitabine is approved for the treatment of patients with 
MDS, including previously treated or untreated, de novo or 
secondary MDS of all FAB subtypes (RA, RARS, RAEB, 
RAEB-T, and CMMoL) and intermediate-1, intermediate-2, 
and high-risk IPSS groups (Dacogen [package insert] 2006). 
Decitabine dosing for MDS is 15 mg/m2 via a 3-hour continu-
ous infusion three times a day for 3 days for the ﬁ  rst treat-
ment cycle, repeated every 6 weeks. It is recommended that 
patients be treated for a minimum of four cycles; however, it 
is noted that a complete or partial response may take longer 
than four cycles. Treatment may be continued as long as the 
patient continues to beneﬁ  t. Patients may be premedicated 
with standard antiemetic therapy.
Decitabine treatment is associated with myelosuppres-
sion, so complete blood counts are recommended before each 
cycle of therapy, or as needed to assess toxicity (Dacogen 
2006). After the ﬁ  rst cycle of therapy, dose adjustments 
and delays may be required and are outlined in the package 
labeling. Clinicians should consider the early administration 
of growth factors and/or antimicrobial agents for prevention 
or treatment of infections. Myelosuppression and worsening 
neutropenia may occur more frequently in the ﬁ  rst or second 
treatment cycles, and may not necessarily indicate progres-
sion of underlying MDS. Decitabine is contraindicated in 
patients with a known hypersensitivity to decitabine and 
carries a pregnancy category D rating.
Preparation and stability
Decitabine should be aseptically reconstituted with 10 mL 
of Sterile Water for Injection (USP) (Dacogen 2006). 
Immediately after reconstitution, the solution should be 
further diluted with 0.9% sodium chloride injection, 5% 
dextrose injection, or lactated Ringer’s injection to a ﬁ  nal 
drug concentration of 0.1–1.0 mg/mL. Unless used within 
15 minutes of reconstitution, the diluted solution must be 
prepared using cold (2 °C–8 °C) infusion ﬂ  uids and stored 
at 2 °C–8 °C (36 °F–46 °F) for up to a maximum of 7 hours 
until administration.
Azacitidine
Azacitidine is the only other approved hypomethylating 
agent for the treatment of MDS. Although similar in struc-
ture to decitabine, azacitidine contains ribose rather than 
deoxribose and is incorporated primarily into RNA and to a 
much lesser extent into DNA. This difference may account 
for the approximately 10-fold higher potency of decitabine 
compared with azacitidine (Creusot et al 1982).
In a randomized phase 3 trial of azacitidine in patients 
with MDS, azacitidine produced results similar to decitabine, 
with an ORR (CR + PR) in the azacitidine arm of 16.2% 
compared to 0% in the supportive care arm (p  0.0001) 
(Silverman et al 2002; Kaminskas et al 2005). The CR rate 
in patients treated with azacitidine was 6.1% compared with 
0% for patients treated with supportive care. Median time to 
AML or death was signiﬁ  cantly increased with azacitidine 
treatment (21 months compared with 13 months for sup-
portive care). As expected for this class of agent, the most 
common treatment-related toxicity was myelosuppression.
Because of the lack of any head-to-head trials, it is 
difﬁ  cult to compare the efﬁ  cacy of decitabine and azacitidine. 
Differences in study design between the two completed phase 
Table 3 Most common adverse events of decitabine
  Decitabine %  Supportive care %
 (n  = 83)*  (n = 81)
Neutropenia 90  72
Thrombocytopenia 89  79
Anemia NOS  82  74
Pyrexia 53 28
Nausea 42 16
Cough 40  31
Petechiae 39  16
Constipation 35  14
Diarrhea NOS  34  16
Hyperglycemia NOS  33  20
Febrile neutropenia  29  6
Leukopenia NOS  28  14
Headache 28  14
Insomnia 28  14
Edema, peripheral  25  16
Vomiting NOS  25  9
Hypoalbuminemia 24  17
Hypomagnesemia 24  7
Pallor 23  12
Pneumonia NOS  22  14
Rigors 22  17
Ecchymosis 22  15
Hypokalemia 22  12
Arthralgia 20  10
*Adverse events reported in 20% of patients in the decitabine group and at a 
rate greater than supportive care in the phase 3 myelodysplastic syndromes trial. 
NOS, not otherwise speciﬁ  ed.Therapeutics and Clinical Risk Management 2007:3(5) 815
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3 trials add to this difﬁ  culty. Patients in the phase 3 azacitidine 
study were able to stay on treatment longer, resulting in 
a median of nine treatment cycles (Silverman et al 2002), 
compared with those in the phase 3 decitabine trial who 
received a median of three treatment cycles (Kantarjian et al 
2006). The median duration of MDS was 7.3 months in the 
decitabine study compared with 2.8 months in the azacitidine 
trial, suggesting that the decitabine patients had more aggres-
sive disease (Silverman et al 2002; Kantarjian et al 2006). In 
addition, response criteria in the azacitidine trial were less 
rigorous, requiring a CR or PR for at least 4 weeks and not 
requiring disappearance of dysplastic changes (Silverman et al 
2002), compared with the decitabine study in which response 
was determined using IWG criteria (Kantarjian et al 2006).
Future considerations
Clinical studies are now under way to evaluate combination 
therapy with decitabine and other agents. Farthest along in 
development is the combination of decitabine and histone 
deacetylase (HDAC) inhibitors such as valproic acid. Results 
from a recent phase 1/2 study of decitabine and valproic 
acid suggest that this combination has signiﬁ  cant activity 
in patients with AML and MDS and is associated with 
changes in histone acetylation and DNA hypomethylation 
(Garcia-Manero et al 2006). Other agents that are being 
studied in combination with decitabine include amsacrine, 
idarubicin, daunorubicin, topotecan, cisplatin, carboplatin, and 
imatinib (Plumb et al 2000; Garcia-Manero and Gore 2005).
Decitabine therapy, alone and in combination with other 
agents, has shown encouraging results in other studies 
involving AML patients (Rivard et al 1981; Momparler et al 
1985; Pinto et al 1989; Petti et al 1993; Lubbert et al 2005). 
Preliminary results from a recent phase 2 study in AML 
patients not eligible for induction chemotherapy suggest 
that decitabine is an active ﬁ  rst-line treatment (Lubbert et al 
2005). Decitabine was administered at a dose of 135 mg/m2 
IV over 72 hours repeated every 6 weeks for up to four 
courses, with all-transretinoic acid (ATRA) administered at 
a dose of 45 mg/m2 per day for 28 days during the second 
course in decitabine-sensitive patients. In the 29 fully evalu-
able patients, a CR was observed in four patients (14%) and 
a PR was observed in ﬁ  ve patients (17%). Toxicities with 
decitabine were similar to those described for MDS, and no 
unexpected toxicities were observed with the combination 
of decitabine plus ATRA.
Although not within the scope of this review, decitabine 
is also being evaluated in chronic myelogenous leukemia 
(CML) (Sacchi et al 1999; Kantarjian et al 2003; Issa et al 
2005) and in some solid tumors including renal, ovarian, 
colorectal, and cervical cancer (van Groeningen et al 1986; 
Abele et al 1987; Sessa et al 1990; Clavel et al 1992; 
Momparler et al 1997; Thibault et al 1998; Schwartsmann 
et al 2000; Plumb et al 2000; Samlowski et al 2005; Stewart 
et al 2005; Gollob et al 2006).
Summary
Results from phase 2 and phase 3 studies indicate that 
decitabine is effective in the treatment of MDS, resulting 
Table 4 Efﬁ  cacy and side effects of three alternative decitabine dosing schedules (Adapted, with permission, from Kantarjian et al 
(2007))
Parameter  Arm A   Arm B   Arm C 
  (5-Day IV)  (10-Day IV)  (5-Day SQ)
No. patients  64  17  14
No. CR/treated (%)  25(39)  4(24)  3(21)
Median number of courses (range)  5(1–18)  9(1–15)  8(1–17)
Median duration of therapy in mos (range)  5.4(1.0–20.4+)  10.8(1.9–17.7+)  9.7(0.5–22.9+)
Median follow-up time (mos)  6.5  15  15
No. (%) still on therapy  39(61)  6(35)  3(21)
Median days to granulocytes recovery to 109/L or above  24  27  14
Median days to platelet recovery to 50 × 109/L or above  20  27  31
Median days to delivery of subsequent courses (range)  35  40  35
No. courses requiring hospitalization (%)  50(12)  23(23)  14(14)
Abbreviation: IV, intravenous; SQ, subcutaneous; CR, complete response. 
Table 5 Decitabine dosing schedules 
Dacogen regimen  IV Dose and schedule  Total dose/course 
FDA approved*   15 mg/m2 over 3 hours  135 mg/m2
  every 8 hours × 3 days
  every 6 weeks 
Active alternative†   20 mg/m2 over  100 mg/m2
  1 hour daily × 5 days
  every 4 weeks
*Kantarjian et al (2006);
†Kantarjian et al (2007)Therapeutics and Clinical Risk Management 2007:3(5) 816
Saba
in durable clinical responses and delayed time to AML 
transformation or death.
Decitabine has been shown to be well tolerated, with 
a toxicity proﬁ  le expected for this class of agents. Recent 
studies suggest that the efﬁ  cacy of decitabine may be fur-
ther optimized by allowing for multiple treatment cycles 
and by using lower-dose schedules such as a schedule of 
20 mg/m2 IV over 1 hour daily for 5 days. Future directions 
for decitabine include its use in combination therapy with 
agents such as HDAC inhibitors and in AML.
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